Aquestive Therapeutics Inc

1. 1

   Election of Directors

   ManagementBoard: FOR

   Elect Gregory B. Brown, M.D., John S. Cochran and Abigail L. Jenkins as Class II directors to serve three-year terms until the 2029 Annual Meeting.

2. 2

   Non-Binding Advisory Vote on the Compensation of Our Named Executive Officers (Say-on-Pay

   ManagementBoard: FOR

   Advisory approval of the compensation of the company’s named executive officers as disclosed in the proxy statement.

   More detail

   This management proposal requests an advisory, non-binding stockholder vote to approve the compensation paid to the company’s named executive officers as disclosed in this proxy statement. Management frames the program as a pay-for-performance structure composed of base salaries, annual cash incentive bonuses tied to financial and strategic objectives, and long-term equity awards (RSUs, PSUs with specified performance price vesting levels, and stock options) intended to align executive incentives with stockholder value and retention. The Compensation Committee, with assistance from an independent consultant, designed target bonus levels and equity mixes (including time-based RSUs for retention, PSUs to tie pay to stock-price performance measured over multi-year pricing periods, and options to reward appreciation) and applied standard vesting schedules and performance metrics. The proposal is advisory only and does not alter the Compensation Committee’s or Board’s fiduciary duties, but the committee states it will consider the vote outcome when setting future pay. In support of approval, the Board emphasizes competitive benchmarking, oversight processes, and the disclosure of severance/change-in-control protections and clawback/independence policies that the committee believes mitigate risk and align interests. Opposing views (if any from investors) are not presented in the filing, but the company discloses pay-versus-performance tables and detailed compensation tables to allow assessment of realized versus targeted pay. Company-specific context includes the use of PSUs with defined threshold/target/maximum Performance Prices ($6.00/$7.00/$8.00) measured over defined pricing periods, and employment agreements that provide severance and change-in-control protections—factors that may influence investor assessment of alignment and potential dilution. The Board’s recommendation to vote "FOR" is grounded in its view that the structure supports strategic objectives, retention of key executives, and alignment with long-term stockholder value, while noting the advisory nature of the vote and its commitment to consider stockholder feedback in future compensation decisions.

3. 3

   Ratification of Selection of Independent Registered Public Accounting Firm

   ManagementBoard: FOR

   Ratify the Audit Committee’s selection of KPMG LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

Upcoming shareholder meetings at Aquestive Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Aquestive Therapeutics Inc 2026 annual meeting?

Aquestive Therapeutics Inc (AQST) holds its 2026 annual shareholder meeting on Wednesday, June 10, 2026.

What is the record date for the Aquestive Therapeutics Inc 2026 meeting?

The record date for the Aquestive Therapeutics Inc 2026 meeting is Monday, April 13, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Aquestive Therapeutics Inc's 2026 meeting?

The board is presenting 3 director nominees at the Aquestive Therapeutics Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Aquestive Therapeutics Inc 2026 meeting?

Shareholders will vote on 3 proposals at the Aquestive Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.